AD is an NDD, characterized by progressive neuronal and synaptic loss and biochemical abnormalities, including the deposition of extracellular amyloid beta (Aβ) plaques, tau hyperphosphorylation, and mitochondrial dysfunction, mainly in the cerebral cortex, with a bigger impact on the hippocampus [32]. The gene discussed is MAPT; the disease is Alzheimer disease.